The Course of Low Back Pain
The Course of Low Back Pain: a Prospective Cohort Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Amersfoort, Netherlands
- Fysius Amersfoort
-
Arnhem, Netherlands
- Fysius Arnhem
-
Eindhoven, Netherlands
- Fysius Eindhoven
-
Nijmegen, Netherlands
- Fysius Nijmegen
-
Rotterdam, Netherlands
- Fysius Rotterdam
-
Winterswijk, Netherlands
- Fysius Winterswijk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Low back pain
- Age 18 years or older
Exclusion Criteria:
- Pregnancy
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional Limitations
Time Frame: Measurement at baseline
|
Measured with Patient Specific Scale (0=no limitation, 100=impossible to perform) and Oswestry Disability Index (0=no limitation, 100=very limited)
|
Measurement at baseline
|
|
Functional Limitations
Time Frame: Measurement at 6 weeks
|
Measured with Patient Specific Scale (0=no limitation, 100=impossible to perform) and Oswestry Disability Index (0=no limitation, 100=very limited)
|
Measurement at 6 weeks
|
|
Functional Limitations
Time Frame: Measurement at 12 weeks
|
Measured with Patient Specific Scale (0=no limitation, 100=impossible to perform) and Oswestry Disability Index (0=no limitation, 100=very limited)
|
Measurement at 12 weeks
|
|
Functional Limitations
Time Frame: Measurement at 26 weeks
|
Measured with Patient Specific Scale (0=no limitation, 100=impossible to perform) and Oswestry Disability Index (0=no limitation, 100=very limited)
|
Measurement at 26 weeks
|
|
Functional Limitations
Time Frame: Measurement at 52 weeks
|
Measured with Patient Specific Scale (0=no limitation, 100=impossible to perform) and Oswestry Disability Index (0=no limitation, 100=very limited)
|
Measurement at 52 weeks
|
|
Recovery rate
Time Frame: 26 weeks after inclusion
|
Global Perceived Effect (7-point Likert-scale where 0=much worse, 7=completely recovered)
|
26 weeks after inclusion
|
|
Recovery rate
Time Frame: 52 weeks after inclusion
|
Global Perceived Effect (7-point Likert-scale where 0=much worse, 7=completely recovered)
|
52 weeks after inclusion
|
|
Pain with Numeric Pain Rating Scale
Time Frame: measurement at baseline
|
Numeric Pain Rating Scale (0= no pain, 10= maximum pain)
|
measurement at baseline
|
|
Pain with Numeric Pain Rating Scale
Time Frame: measurement at 6 weeks
|
Numeric Pain Rating Scale (0= no pain, 10= maximum pain)
|
measurement at 6 weeks
|
|
Pain with Numeric Pain Rating Scale
Time Frame: measurement at 12 weeks
|
Numeric Pain Rating Scale (0= no pain, 10= maximum pain)
|
measurement at 12 weeks
|
|
Pain with Numeric Pain Rating Scale
Time Frame: measurement at 26 weeks
|
Numeric Pain Rating Scale (0= no pain, 10= maximum pain)
|
measurement at 26 weeks
|
|
Pain with Numeric Pain Rating Scale
Time Frame: measurement at 52 weeks
|
Numeric Pain Rating Scale (0= no pain, 10= maximum pain)
|
measurement at 52 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 109643
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.